MeridianResearch
← Research notes

Mechanisms 2026-03-25 · 2 min read

Semax and Selank: two neuropeptides, two mechanisms, one structural origin

Semax and Selank both derive from ACTH-fragment pharmacology but activate different primary mechanisms — BDNF and dopaminergic signaling for Semax, GABA-A allosteric modulation for Selank. A look at the published record for each.

Semax and Selank are two short regulatory peptides that share an origin in the study of endogenous signaling fragments yet derive from distinct parent families. Both have been studied in preclinical models for their reported modulation of central signaling pathways, and both illustrate how small sequence modifications can confer markedly different enzymatic stability. This note summarizes their structural origins and the mechanistic literature surrounding each.

Structural origin of Semax

Semax is an analog of the ACTH(4-10) fragment, extended at the C-terminus with a Pro-Gly-Pro tripeptide. ACTH(4-10) belongs to the melanocortin family, a group of peptides cleaved from the proopiomelanocortin precursor that interact with melanocortin receptor subtypes in the central nervous system. The heptapeptide core retains the message sequence implicated in central melanocortin signaling while shedding the adrenocorticotropic activity associated with the full ACTH molecule.

Structural origin of Selank

Selank is a synthetic analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from the Fc region of immunoglobulin G. Like Semax, Selank carries a Pro-Gly-Pro extension. Tuftsin and its analogs belong to the broader class of regulatory peptides studied for their reported interactions with immunomodulatory and central signaling systems, placing Selank in a different lineage than the melanocortin-derived Semax.

Reported BDNF modulation

A recurring theme in the preclinical literature on both peptides is reported modulation of brain-derived neurotrophic factor (BDNF) and its associated signaling cascade. Published studies in rodent models have described changes in BDNF and TrkB expression following administration of each compound, a finding researchers have used to frame hypotheses about neurotrophic signaling. These are mechanistic observations from animal and cell-based systems and should be interpreted within those experimental contexts.

Enzymatic stability of the modified sequences

Native short peptides are rapidly degraded by aminopeptidases and other proteolytic enzymes. The Pro-Gly-Pro extension common to both Semax and Selank has been reported to slow enzymatic cleavage, with the proline residues conferring resistance at the terminus. This conferred stability is a frequent rationale in the medicinal-chemistry literature for appending proline-rich motifs to otherwise labile peptide cores.

Analytical considerations

For laboratory reference work, identity and purity of both peptides are typically confirmed by reversed-phase HPLC for purity and by LC-MS for mass confirmation of the intended sequence. Because the two compounds share a Pro-Gly-Pro motif but differ in their core sequences, mass spectrometric identity confirmation is essential to distinguish them and to verify that no truncated or modified species are present.

These materials are for laboratory research use only and are not for human or veterinary use.

Intended use:
For laboratory research use only.
Prohibited use:
Not for human or veterinary use.